Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHA:600572)

SHA:600572 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,322	2,570	2,468	2,573	1,575
Trading Asset Securities	-	-	-	-	1.8
Cash & Short-Term Investments	1,322	2,570	2,468	2,573	1,577
Cash Growth	-48.56%	4.13%	-4.09%	63.19%	-7.47%
Accounts Receivable	1,665	1,756	1,638	1,671	1,405
Other Receivables	87.74	38.22	59.41	84.42	96.53
Receivables	1,753	1,794	1,697	1,755	1,501
Inventory	1,266	1,333	1,128	1,044	961.46
Prepaid Expenses	-	0.61	0.89	1.02	4.78
Other Current Assets	78.44	77.26	101.74	92.17	92.95
Total Current Assets	4,419	5,775	5,395	5,466	4,138
Property, Plant & Equipment	3,051	3,048	3,220	3,251	3,033
Long-Term Investments	1,774	1,723	1,629	1,881	1,435
Goodwill	184.72	184.72	184.72	184.72	172.61
Other Intangible Assets	349.19	355.45	390.79	362.43	377.82
Long-Term Deferred Tax Assets	41.16	78.94	55.46	27.5	32.67
Long-Term Deferred Charges	67.46	46.35	40.66	66.81	51.47
Other Long-Term Assets	15.34	25.86	14.82	34.78	38.61
Total Assets	9,902	11,238	10,931	11,274	9,279
Accounts Payable	984.41	819.53	629.13	540.19	270.97
Accrued Expenses	179.85	1,205	1,005	873.5	821.29
Short-Term Debt	210.56	849.71	717.73	1,344	1,748
Current Portion of Long-Term Debt	93.3	77.79	138.63	129.65	-
Current Portion of Leases	-	4.4	6.15	4.63	-
Current Income Taxes Payable	115.5	56.45	51.38	28.5	62.93
Current Unearned Revenue	37.68	43.65	113.3	36.68	41.97
Other Current Liabilities	895.13	115.87	128.07	210.8	307.18
Total Current Liabilities	2,516	3,173	2,789	3,168	3,253
Long-Term Debt	117.87	305.03	330.3	9.5	502.71
Long-Term Leases	2.05	0.72	3.97	4	-
Long-Term Unearned Revenue	116.21	141.11	154.22	146.83	98.61
Long-Term Deferred Tax Liabilities	235.6	268.27	328.79	310.3	74.31
Other Long-Term Liabilities	0.94	0.93	0.92	0.92	0.73
Total Liabilities	2,989	3,889	3,607	3,639	3,929
Common Stock	2,583	2,570	2,570	2,570	2,667
Additional Paid-In Capital	285.66	210.32	149.54	359.76	677.13
Retained Earnings	4,251	4,261	4,194	4,271	2,267
Treasury Stock	-299.99	-	-	-	-585.15
Comprehensive Income & Other	-0.11	-0.01	0.1	0.27	0.28
Total Common Equity	6,820	7,041	6,914	7,201	5,026
Minority Interest	92.97	308.58	410.18	434.01	323.25
Shareholders' Equity	6,913	7,350	7,324	7,635	5,349
Total Liabilities & Equity	9,902	11,238	10,931	11,274	9,279
Total Debt	423.77	1,238	1,197	1,492	2,251
Net Cash (Debt)	898.34	1,332	1,271	1,082	-674.33
Net Cash Growth	-32.57%	4.81%	17.53%	-	-
Net Cash Per Share	0.36	0.52	0.50	0.42	-0.27
Filing Date Shares Outstanding	2,371	2,570	2,570	2,570	2,570
Total Common Shares Outstanding	2,371	2,570	2,570	2,570	2,570
Working Capital	1,902	2,603	2,606	2,298	884.71
Book Value Per Share	2.88	2.74	2.69	2.80	1.96
Tangible Book Value	6,286	6,501	6,338	6,654	4,476
Tangible Book Value Per Share	2.65	2.53	2.47	2.59	1.74
Buildings	-	2,250	2,138	2,055	2,064
Machinery	-	2,655	2,279	1,888	1,921
Construction In Progress	-	238.37	661.93	1,068	598.64

Source: S&P Global Market Intelligence. Standard template. Financial Sources.